Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab for early moderately to severely active Crohn's disease
ChiCTR2200063233Phase 4Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vedolizumab in Crohn's disease, sponsored by Sir Run-Run Shaw Hospital. Primary endpoints: Clinical remission rate and Endoscopic remission rate. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
vedolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on ChiCTR2200063233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063233.